Page results
-
This page describes a surgical keyhole procedure to remove fibroids, called a laparoscopic myomectomy.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
A team of clinician scientists at UCLH have identified the factors which predict full hearing recovery, with the strongest predictor being treatment with steroids within seven days of a sudden drop in hearing.
-
EMIS outage caused backlog of result messages via Keystone
-
This page provides information about the Palliative care and symptom control team
-
Contact details of clinical lead adults and lead paediatrics
-
This patient information explains an inguinal gonadectomy.
-
This patient information explains laparoscopic gonadectomy.
-
Information about hyperthermic intraperitoneal chemotherapy (HIPEC), including about the risks and benefits, and alternatives to the treatment.
File results
-
FOI/2023/0211 - Services available to older residents
-
FOI/2023/0212 - Training provided to clinical staff for use of medical devices
-
FOI/2023/0222 - Contact details for senior screening and immunisations staff
-
FOI/2023/0231 - Patients seen at A&E with symptoms of taking nitrous oxide gas
-
FOI/2023/0237 - Software solution to manage patient e-consent for school vaccinations/ immunisations and waitlist validation
-
FOI/2023/0250 - Early Access to Medicines Scheme (EAMS)
-
FOI/2023/0251 - Vials used for immunoglobulin drugs - January to March 2023
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0270 - Total agency spend and midwifery spend from 2018/19 to 2022/23
-
FOI/2023/0360 - Minutes of Board of Director meetings and Declarations of Interests (DoI) statements 2008-2023